Buprenorphine for Pain: A Transition Guide from Full Agonist Opioid Prescriptions

General Considerations

1. Buprenorphine is a Schedule III medication – refills are permitted up to 6 months; Rx can be phoned in.
2. It is associated with lower misuse and overdose risk compared to Schedule II full-agonist opioids.
3. It offers better mood effect while other opioid side effects may be similar to full-agonist opioids.
4. Little or no drug tolerance is experienced over time.
5. Urine testing: Know your lab. Buprenorphine is not detected by the "opioid" test on enzyme immunoassay (EIA) screens.
6. Buprenorphine no longer requires an X-waiver for any indication, including pain

Opioid Patient Pre-treatment Information

1. Have a clear diagnosis and plan for your patient.
2. Agree on treatment goals and plan to discontinue if the medication is not working (lack of functional improvement, identification of a safer medication regimen or improved pain control, etc.).
3. Identify any complexities that may require subspecialty care: uncontrolled major psychiatric disorder, current benzodiazepine use disorder, current alcohol use disorder, other active substance use disorder, and pregnancy.
4. Check the Prescription Drug Monitoring Program (PDMP).
5. If patient is using tramadol, no buprenorphine induction protocol needed.
6. Perform urine drug screening with confirmatory testing if results are unexpected.
7. Offer counseling services.
8. Instruct patient on the proper use of transdermal, buccal, or sublingual medication.
9. In general, prescribe the abuse deterrent, buprenorphine/naloxone (Suboxone™ or other) formulations

Understand Morphine Mg Equivalent Daily Dosing (MMED) - (MS = oral morphine mg). See Table 1.

Table 1

Opioid	Relative potency	Opioid	Relative potency	Opioid	Relative potency
Tapentadol mg	= MS mg x 0.4 *	Oxycodone	= MS x 1.5 **	Hydromorphone	= MS x 4-5
Hydrocodone	= MS	Heroin	= MS x 2.5	Fentanyl >	1 mcg/hr approx. 2 mg/day MS
Butorphanol	= MS	Oxymorphone	= MS x 3-4	Methadone	= 4-20 x MS potency

* Example: Tapentadol 100 mg = 40 mg morphine equivalent ** Example: Oxycodone 20 mg = 30 mg morphine

Prescribing Principles

Transdermal buprenorphine (Butrans™ or generic)



1. Dose range 5-20 mcg patch applied once/week, covers up to 80 MMED. Start patch 1/week as in Table 2.

Table 2

Current MMED	Recommended Initial Dose
≤ 15 (includes opioid naïve patient)	5 mcg/hr
15-29	7.5 mcg/hr
≥ 30	10 mcg/hr

2. If needed during build-up in first day only, patient may use their full agonist medication for 1 or 2 doses, then stop.
3. Wait 7 days to titrate transdermal buprenorphine.
4. Patches may be cut if necessary.
5. Insurance often will not cover transdermal buprenorphine.
6. Do not stop before, during, or after surgery or procedures. Supplement with NSAID or oral opioid if needed.
7. Irritated skin at patch site might be improved by pretreatment of skin with nasal fluticasone.

Buccal buprenorphine (Belbuca™)



1. Dose range 75-1800 mcg/day divided to BID or TID doses, covers up to 160 MMED. Start strips as in Table 3.

   Table 3

Current MMED	Recommended Initial Daily Dose
≤ 30 (includes opioid naïve patient)	75-150 mcg divided to BID or TID
30-90	150-300 mcg divided as above
≥ 90	300-600 mcg divided as above

2. If needed during build-up in first day only, patient may use their full agonist medication for 1 or 2 doses, then stop.
3. Do not titrate buccal buprenorphine for at least 4 days.
4. Insurance often will not cover buccal buprenorphine.
5. Do not stop before, during, or after surgery or procedures. Supplement with NSAID or oral opioid if needed.

Sublingual buprenorphine (Suboxone, Zubsolv, geneic buprenorphine/naloxone strips or tablets)

1. Films may be cut into halves or even smaller.
2. Films should be held under the tongue for 5 minutes; tablets for 10 minutes, without eating, drinking, talking.
3. Use of the Clinical Opioid Withdrawal Scale (COWS) is not necessary for pain patients.
4. Tramadol does not require an opioid free interval for induction
5. Avoid weekend calls for refills – write prescriptions in 1-4 week (7, 14,21,28 day) amounts, not 30 days.
6. With a clear plan, buprenorphine may be initiated at home.
7. Write "for pain" on the buprenorphine Rx when appropriate.
8. Delay benzodiazepine taper until stable after conversion to buprenorphine.
9. Dose TID or even QID for pain, BID for OUD.
10. Check for insurance coverage.

Choice of sublingual buprenorphine dosing ranges and transition protocol is based on opioid(s) currently being used (short-intermediate-long acting) as in Table 4.

Table 4

1. Short-acting opioids (codeine, tapentadol, hydrocodone, morphine IR, oxycodone IR, oxymorphone IR, hydromorphone)				
Preparation	Opioid-free interval	Transition dosing	Initial target dose in (mg/day)	Comments
If prior pill dose is > 180 MMED, taper to ≤ 180 by 10% of total every 4 days.	12 hours	1 mg SL Q30 min x 4 doses (OK to combine the third and fourth doses if there is regression of pain or withdrawal symptoms at 1 hr). After 4 hr, continue that day with target dose.	• < 50 MMED → 0.5-3 (divide into 3 doses for pain patients) • 50-150 MMED → 3-6 • > 150 MMED → 6-8	• For OUD patients, divide total into 1-2 doses/day, use higher end of range. • For patients with pain > OUD, divide into 3-4 doses/day at lower end of range
2. Intermediate-acting opioids (morphine ER, oxycodone ER)				
Preparation	Opioid-free interval	Transition dosing	Initial target dose (mg/day)	Comments
• If on Kadian, convert to equal amount of morphine ER *** divided into 3 doses. • If prior dose is > 180 MMED, taper to ≤ 180 by 10% of total every 4-7 days	12 hours	1 mg SL Q30 min x 4 doses (OK to combine the third and fourth doses if there is regression of pain or withdrawal symptoms at 1 hr). After 4 hr, continue that day with target dose.	• < 50 MMED → 0.5-3 (divide into 3 doses for pain patients) • 50-150 MMED → 3-6 • > 150 MMED → 6-8	• For OUD patients, divide total into 1-2 doses/day, use higher end of range • For patients with pain > OUD, divide into 3-4 doses/day at lower end of range

*** Example: MS Contin or its generic

Table 4 Continued

3. Long-acting opioids (fentanyl patches, methadone) – "Bridging" with short-acting opioid permits symptom control during clearance. IN GENERAL, WE RECOMMEND CONFIRMING THE PLAN WITH A CONSULTANT FAMILIAR WITH THIS PROCESS				
Preparation (get help if not able to taper) *Fentanyl prior dose* • > 75 mcg/h – taper by 12 mcg every 6-9 days • ≤ 75 mcg/h, proceed to "bridging" *Methadone prior dose* • ≤ 80 mg/day – taper by 5 mg each week • > 80 mg/day – taper by 10 mg each week	"Bridging" treatment 1. Stop fentanyl or methadone on the morning of day 1. Begin morphine IR 30 mg 4-5 times per day for 5 days (7 days, if obese) 2. On the 5th night, stop morphine IR 3. Start induction on the 6th morning after no opioid x 12 h	Transition dosing After 12 hrs off "bridge," 1 mg SL Q30 min x 4 doses (OK to combine the third and fourth doses if there is regression of pain or withdrawal symptoms at 1 hr). After 4 hr, continue that day with target dose.	Initial buprenorphine target dose (mg/day) • < 50 MMED → 0.5-3 (divide into 3 doses for pain patients) • 50-150 MMED → 3-6 • > 150 MMED → 6-8	Comments • For OUD patients, divide total into 1-2 doses/day, use higher end of range. • For patients with pain > OUD, divide into 3-4 doses/day at lower end of range **WARNING: Transition from long-acting opioids can be more challenging than from shorter acting agonists.** **SUGGESTION: Seek assistance from an experienced consultant.**

This resource guide does not provide detailed guidance for microdosing, which is an alternative method for conversion from full-agonist opioid to buprenorphine that avoids the requirement of an opioid-free interval.

Additional Resources:

- Converting prescription opioid doses into MME: https://www.mdcalc.com/morphine-milligram-equiva¬lents-mme-calculator
- Butrans official site: https://butrans.com/dosing/prescribing-considerations.html
- Belbuca official site: https://www.belbuca.com/hcp#
- Michigan Medicine Ambulatory Pain Management Guidelines: https://michmed-public.policystat.com/policy/7109483/latest/

References:

- Cohen, Shawn M., Melissa B. Weimer, Ximena A. Levander, Alyssa M. Peckham, Jeanette M. Tetrault, and Kenneth L. Morford. "Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach." Journal of Addiction Medicine Publish Ahead of Print (December 23, 2021). https://doi.org/10.1097/ADM.0000000000000945.
- Kornfeld, Howard, and Heidi Reetz. "Transdermal Buprenorphine, Opioid Rotation to Sublingual Bu¬prenorphine, and the Avoidance of Precipitated Withdrawal: A Review of the Literature and Demonstra¬tion in Three Chronic Pain Patients Treated With Butrans." American Journal of Therapeutics, 2015, 7.
- Raheemullah, Amer, and Anna Lembke. "Initiating Opioid Agonist Treatment for Opioid Use Disorder in the Inpatient Setting: A Teachable Moment." JAMA Internal Medicine 179, no. 3 (March 1, 2019): 427. https://doi.org/10.1001/jamainternmed.2018.6749.
- Webster, Lynn, Jeffrey Gudin, Robert B Raffa, Jay Kuchera, Richard Rauck, Jeffrey Fudin, Jeremy Adler, and Theresa Mallick-Searle. "Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion." Pain Medicine 21, no. 4 (April 1, 2020): 714–23. https://doi.org/10.1093/pm/pnz356.
- Weimer, Melissa B., Michael Guerra, Gina Morrow, and Kathleen Adams. "Hospital-Based Bupreno¬phine Micro-Dose Initiation." Journal of Addiction Medicine 15, no. 3 (May 2021): 255–57. https://doi.org/10.1097/ADM.0000000000000745.
- Zimmerman, Amanda, Rami Bikdash, and Richard Rauck. "Conversion of Schedule II Opioids to Bu¬prenorphine Buccal Film: A Retrospective Analysis." Pain Medicine 22, no. 5 (May 21, 2021): 1109–15. https://doi.org/10.1093/pm/pnaa226.

Insurance coverage for various buprenorphine formulations may present a barrier at this time.

These guidelines should not be construed as including all proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient.

Source: Dr. Daniel Berland and the Michigan Opioid Collaborative

This material was prepared by the IPRO QIN-QIO, a Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity here in does not constitute endorsement of that product or entity by CMS or HHS. 12SOW-IPRO-QIN-TA-AA-23-980

04/20/23 Rev 2